title: Dutch orthopedic thromboprophylaxis: a 5-year follow-up survey.
abstract: OBJECTIVE
  Previous surveys in the Netherlands have revealed that guidelines regarding orthopedic thromboprophylaxis were not followed and that a wide variation in protocols exists. This survey was performed to assess the current use of thromboprophylactic modalities and to compare it with the results of a previous survey.
  
  
  METHODS
  All departments of orthopedic surgery in the Netherlands were sent a follow-up survey on venous thromboprophylaxis, and the data obtained were compared to the results of a survey performed 5 years earlier.
  
  
  RESULTS
  All departments used pharmacological thromboprophylaxis following arthroplasties of the hip and knee. Low-molecular-weight heparin (LMWH) was used most frequently (79%) of the departments, followed by fondaparinux (13%). 5 years earlier, coumarin treatment was the predominant prophylaxis (79%). All departments prescribed pharmacological prophylaxis after femoral and tibial fractures; 78% used LMWH. Prophylaxis was continued for 6 weeks in 85% of cases. LMWH treatment was initiated on the day before surgery in 31% of cases (65% in the previous survey), perioperatively in 55%, and in the evening following surgery in 24%. In general, for daycare surgery and arthroscopies either no prophylaxis was given or a LMWH was given for 1 day. After anterior cruciate ligament reconstruction, 94% of departments prescribed some form of pharmacological prophylaxis.
  
  
  CONCLUSIONS
  The use of pharmacological prophylaxis after arthroplasty of the hip and knee and also after fracture surgery around the hip and knee is common practice in the Netherlands. In 5 years, the widely used coumarin derivates have been largely replaced with LMWH.
authors.affiliation: Department of Orthopedic Surgery, Isala Clinics, Zwolle, the Netherlands.
authors.forename: Harmen B
authors.initials: HB
authors.lastname: Ettema
authors.forename: Marieke C
authors.initials: MC
authors.lastname: Mulder
authors.forename: Michael T
authors.initials: MT
authors.lastname: Nurmohamed
authors.forename: Harry R
authors.initials: HR
authors.lastname: Büller
authors.forename: Cees C P M
authors.initials: CC
authors.lastname: Verheyen
mesh_terms: D016118:Anterior Cruciate Ligament / Q000601:surgery; D000925:Anticoagulants / Q000008:administration & dosage*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D003374:Coumarins / Q000008:administration & dosage; D005500:Follow-Up Studies; D000077425:Fondaparinux; D005593:Fracture Fixation, Internal / Q000009:adverse effects; D019983:Guideline Adherence; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D009426:Netherlands; D011134:Polysaccharides / Q000008:administration & dosage; D010818:Practice Patterns, Physicians'; D053828:Stockings, Compression; D011795:Surveys and Questionnaires; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D003374:Coumarins; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; C030123:coumarin; D000077425:Fondaparinux